Article Text

Download PDFPDF

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
  1. E N van Roon1,
  2. T L T A Jansen2,
  3. M A F J van de Laar3,
  4. M Janssen4,
  5. J P Yska1,
  6. R Keuper1,
  7. P M Houtman2,
  8. J R B J Brouwers5
  1. 1Department of Clinical Pharmacy and Clinical Pharmacology, Medisch Centrum Leeuwarden, Leeuwarden, Netherlands
  2. 2Department of Rheumatology, Medisch Centrum Leeuwarden
  3. 3Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands
  4. 4Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands
  5. 5Groningen University Institute for Drug Exploration (GUIDE), Subdivision Pharmacotherapy and Pharmaceutical Care, Netherlands
  1. Correspondence to:
    Mr E N van Roon
    Department of Clinical Pharmacy and Pharmacology, Medical Centre Leeuwarden, PO Box 888, 8901 BR Leeuwarden, Netherlands;

Statistics from


    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.